Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.39 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170438 | 0.89 | CYP11B2 (0.46) | DCTPP1CYP11B2CYP19A1CYP11B1SLC2A1 | |
| SCHEMBL17472244 | 0.87 | CYP11B2 (0.44) | CYP11B2CYP19A1CYP11B1SLC2A1SLC2A3 | |
| SCHEMBL17458875 | 0.85 | ALDH1A1 (0.49) | MAPTALDH1A1LMNAPKMHTT | |
| SCHEMBL17458884 | 0.85 | CYP19A1 (0.41) | DCTPP1CYP11B2CYP19A1CYP11B1MAPT | |
| SCHEMBL28842825 | 0.84 | CYP19A1 (0.43) | DCTPP1CYP11B2CYP19A1CYP11B1VCAM1 | |
| SCHEMBL17458953 | 0.84 | CYP19A1 (0.40) | DCTPP1CYP11B2CYP19A1CYP11B1MAPT | |
| SCHEMBL17458926 | 0.82 | SOS1 (0.49) | SLC2A1PTGDR2KDM4EALDH1A1LMNA | |
| SCHEMBL28842491 | 0.81 | SMN1; SMN2 (0.41) | DCTPP1CYP11B2CYP19A1CYP11B1MAPT | |
| SCHEMBL17459012 | 0.81 | CYP11B1 (0.51) | CYP11B2CYP19A1CYP11B1MAPTAR | |
| SCHEMBL17470460 | 0.81 | POLB (0.41) | MAPTKDM4EALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074814-A | Glucose transport inhibitor | 拜耳制药股份公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | DCTPP1 806/4885CYP11B2 512/4885CYP19A1 1271/4885 |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | DCTPP1 747/4885CYP11B2 356/4885CYP19A1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.